How Does Moderna Make its Money?
Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The company’s flagship product is Spikevax, the COVID-19 vaccine that generated over $36B in cumulative revenue since its 2021 launch. Moderna has since expanded to mRESVIA (RSV vaccine, approved 2024) and has a pipeline of 40+ mRNA programs spanning infectious diseases, oncology, rare diseases, and autoimmune conditions.
Revenue Breakdown
| Product | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Spikevax (COVID-19 Vaccine) | $3.2B | $6.7B | -52.2% |
| mRESVIA (RSV Vaccine) | $0.15B | — | New |
| Other/Grant Revenue | $0.35B | $0.3B | +16.7% |
| Total Revenue | $3.76B | $6.84B | -45.0% |
Spikevax (COVID-19) — 85% of Revenue
Moderna’s mRNA-based COVID-19 vaccine. Revenue has declined sharply from the 2022 peak of $18.4B as:
- COVID-19 vaccinations shifted from mass campaigns to annual seasonal boosters
- Competition from Pfizer/BioNTech and Novavax
- Pandemic urgency faded
The COVID vaccine is transitioning to a seasonal respiratory product (fall booster shots), similar to the annual flu vaccine market.
mRESVIA (RSV) — New Product
FDA-approved in May 2024 for adults 60+. The first mRNA-based RSV (respiratory syncytial virus) vaccine. Competes with GSK’s Arexvy and Pfizer’s Abrysvo. Revenue was modest in the first partial year but represents Moderna’s first non-COVID commercial product.
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $3.76B | $6.84B |
| Cost of Sales | $1.80B | $3.60B |
| R&D Expense | $4.75B | $4.85B |
| Operating Income | -$4.35B | -$3.60B |
| Net Income | -$3.60B | -$4.71B |
Key Financial Metrics
- Gross Margin: 52.1% — Compressed from 79% at peak as lower COVID vaccine volumes reduce manufacturing efficiency and Moderna takes inventory writedowns.
- R&D Spending: $4.75B — Moderna is spending more on R&D than it generates in revenue. The company is betting its cash reserves ($10B+) that the mRNA platform will produce multiple blockbuster products.
- Cash & Investments: $10.8B — Moderna built a massive cash stockpile from COVID revenues. This funds the pipeline through ~2028 without additional financing.
- Net Loss: -$3.6B — Operating at a significant loss as R&D spending exceeds revenue.
What to Watch
- Pipeline execution — Moderna has 40+ mRNA programs. The most important near-term catalysts:
- mRNA-1083 (flu + COVID combo): Phase 3 results expected 2025. Could be a massive market.
- mRNA-1345 (next-gen RSV): Improved formulation
- INT-1 (individualized cancer vaccine): Personalized neoantigen vaccine with Merck for melanoma. Phase 3 underway.
- COVID seasonalization — Can Moderna maintain $3-4B+ in annual COVID vaccine revenue as a seasonal product? Pricing, market share, and booster uptake rates are key.
- Cash runway — With $10.8B in cash and ~$4B in annual cash burn, Moderna has ~3 years of runway. Pipeline successes must materialize before the cash runs out.
- Flu + COVID combination vaccine — If approved, a single-shot combo targeting both flu and COVID could capture a large share of the annual respiratory vaccine market.
- Oncology/rare disease mRNA — Personalized cancer vaccines and rare disease enzyme replacement therapies represent the long-term platform potential. Still early but scientifically groundbreaking.